• Live from TTLC 2026: Emerging Molecular Targets in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer ConsideredShow Notes
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC.
Guests: Kelsey Pan, MD, MPH Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section Emory University Winship Cancer Institute
Rajat Thawani, MD Assistant Professor of Medicine Division of Hematology and Oncology Knight Cancer Institute, OHSU
More from Lung Cancer Considered
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
Recorded at the 2026 IASLC World Conference on Lung Cancer in Seoul, this special Early Career Takeover episode explores what this annual meeting offers to researchers and clinicians at the start of their careers.
The WHO Eastern Mediterranean Region (EMRO) faces unique challenges around exposures, non-conventional smoking, lung cancer screening, molecular profiling, and evolving therapies in lung cancer. To address this, the inaugural joint IASLC/EMRO workshop took place at the 2026 World Conference on Lung Cancer (WCLC) in Seoul.